Logo image of AQS.CA

Aequus Pharmaceuticals Inc (AQS.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:AQS - CA0076361033 - Common Stock

0.005 CAD
0 (0%)
Last: 4/25/2025, 7:00:00 PM
Fundamental Rating

0

Overall AQS gets a fundamental rating of 0 out of 10. We evaluated AQS against 35 industry peers in the Pharmaceuticals industry. AQS has a bad profitability rating. Also its financial health evaluation is rather negative. AQS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AQS had negative earnings in the past year.
In the past year AQS has reported a negative cash flow from operations.
AQS had negative earnings in each of the past 5 years.
AQS had a negative operating cash flow in each of the past 5 years.
AQS.CA Yearly Net Income VS EBIT VS OCF VS FCFAQS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

AQS has a Return On Assets of -311.85%. This is amonst the worse of the industry: AQS underperforms 97.06% of its industry peers.
Industry RankSector Rank
ROA -311.85%
ROE N/A
ROIC N/A
ROA(3y)-168.11%
ROA(5y)-144.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQS.CA Yearly ROA, ROE, ROICAQS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

AQS's Gross Margin of 53.46% is fine compared to the rest of the industry. AQS outperforms 79.41% of its industry peers.
AQS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AQS.CA Yearly Profit, Operating, Gross MarginsAQS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

AQS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AQS has about the same amount of shares outstanding.
AQS has a worse debt/assets ratio than last year.
AQS.CA Yearly Shares OutstandingAQS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
AQS.CA Yearly Total Debt VS Total AssetsAQS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M

2.2 Solvency

AQS has an Altman-Z score of -67.10. This is a bad value and indicates that AQS is not financially healthy and even has some risk of bankruptcy.
AQS's Altman-Z score of -67.10 is on the low side compared to the rest of the industry. AQS is outperformed by 94.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.1
ROIC/WACCN/A
WACC2.24%
AQS.CA Yearly LT Debt VS Equity VS FCFAQS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 0.05 indicates that AQS may have some problems paying its short term obligations.
AQS's Current ratio of 0.05 is on the low side compared to the rest of the industry. AQS is outperformed by 97.06% of its industry peers.
AQS has a Quick Ratio of 0.05. This is a bad value and indicates that AQS is not financially healthy enough and could expect problems in meeting its short term obligations.
AQS's Quick ratio of 0.03 is on the low side compared to the rest of the industry. AQS is outperformed by 97.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.03
AQS.CA Yearly Current Assets VS Current LiabilitesAQS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

AQS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
The Revenue for AQS has decreased by -29.63% in the past year. This is quite bad
The Revenue for AQS have been decreasing by -28.97% on average. This is quite bad
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.59%
Revenue 1Y (TTM)-29.63%
Revenue growth 3Y-53.85%
Revenue growth 5Y-28.97%
Sales Q2Q%1006.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AQS.CA Yearly Revenue VS EstimatesAQS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
AQS.CA Yearly EPS VS EstimatesAQS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AQS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQS.CA Price Earnings VS Forward Price EarningsAQS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQS.CA Per share dataAQS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aequus Pharmaceuticals Inc

TSX-V:AQS (4/25/2025, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24 2025-04-24
Earnings (Next)05-07 2025-05-07
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.68%
Ins Owner ChangeN/A
Market Cap663.15K
Revenue(TTM)413.20K
Net Income(TTM)-2.68M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.6
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -311.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.46%
FCFM N/A
ROA(3y)-168.11%
ROA(5y)-144.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.03
Altman-Z -67.1
F-Score1
WACC2.24%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-29.63%
Revenue growth 3Y-53.85%
Revenue growth 5Y-28.97%
Sales Q2Q%1006.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.57%
OCF growth 3YN/A
OCF growth 5YN/A

Aequus Pharmaceuticals Inc / AQS.CA FAQ

What is the ChartMill fundamental rating of Aequus Pharmaceuticals Inc (AQS.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to AQS.CA.


What is the valuation status of Aequus Pharmaceuticals Inc (AQS.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to Aequus Pharmaceuticals Inc (AQS.CA). This can be considered as Overvalued.


How profitable is Aequus Pharmaceuticals Inc (AQS.CA) stock?

Aequus Pharmaceuticals Inc (AQS.CA) has a profitability rating of 1 / 10.